Organization (Industry)
Daiichi Sankyo (Germany)
ClinicalTrials.gov lists Daiichi Sankyo (Germany) as lead sponsor of 400 trials, counting the companies grouped under it. Daiichi Sankyo (Germany) itself has 263 active development programs and 122 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 18 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 25 in 2026 and about 38 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (20 to 100), forecasts made part-way through the year were typically off by about 18 percent and ran about 14 percent low against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
Logo Daiichi Sankyo Company, Limited, via Wikimedia Commons, CC BY 2.5. Shown to identify the organization; it may be a registered trademark.
This page covers Daiichi Sankyo (Germany) and 1 company grouped under it: 400 lead-sponsored trials (393 its own, 7 in the grouped companies) and 9 legal-entity registrations (8 its own, 1 in the grouped companies).
Companies grouped under this page (1)
| Company | Lead trials | Legal entities |
|---|---|---|
| Plexxikon (United States) | 7 | 1 |
Disease areas (200)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Lung Neoplasms | 63 |
| Breast Neoplasms | 61 |
| Carcinoma, Non-Small-Cell Lung | 51 |
| Diabetes Mellitus | 43 |
| Hypertension | 36 |
Showing 5 of 200 disease areas.
Trials by start year as sponsor or collaborator (29)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 18 |
| 2025 | 52 |
| 2024 | 33 |
| 2023 | 22 |
| 2022 | 21 |
| 2021 | 34 |
| 2020 | 30 |
| 2019 | 15 |
| 2018 | 21 |
| 2017 | 23 |
Showing 10 of 29 years.
Prediction, not a registry value: median of 36 months from start to primary completion across 34 trials still running at the 2026-10-09 snapshot; registered median of 19 months across 324 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (263)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| PEMBROLIZUMAB | Lung Neoplasms | Phase 3 | 8 |
| PEMBROLIZUMAB | Carcinoma, Non-Small-Cell Lung | Phase 3 | 8 |
| Trastuzumab Deruxtecan | Breast Neoplasms | Phase 3 | 9 |
| Datopotamab Deruxtecan | Carcinoma, Non-Small-Cell Lung | Phase 3 | 6 |
| Datopotamab Deruxtecan | Lung Neoplasms | Phase 3 | 6 |
Showing 5 of 263 active programs.
Approved assets (122)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Olmesartan Medoxomil | 18 |
| Colesevelam | 11 |
| Pexidartinib | 8 |
| Ezetimibe | 6 |
| Amlodipine | 5 |
Showing 5 of 122 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 61% hit target (n=114) | 42% on time (n=115) |
Journals published in (266)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| The New England journal of medicine | 36 |
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 30 |
| Circulation | 29 |
| Journal of the American College of Cardiology | 28 |
| Journal of the American Heart Association | 22 |
Showing 5 of 266 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 551 | 99 | 2025-12-30 |
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| VAI | 8 |
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 7 | 2025-05-28 |
Manufacturing and distribution sites (3)
Shown in this order: severity rank then name.
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| Daiichi Sankyo Co., Ltd. | Kanagawa, JP | EMA, FDA | |
| Daiichi Sankyo Chemical Pharma Co. Ltd. | Iwaki, JP | EMA | |
| DAIICHI SANKYO PROPHARMA CO., LTD., Takatsuki Plant | Takatsuki, JP | EMA |
Organization relationships (49)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Merck & Co., Inc., Rahway, NJ, USA (United States) | Co sponsors trial with | 30 |
| Syneos Health (United States) | Uses vendor | 5 |
| Government of the United States of America | Co sponsors trial with | 4 |
| Iqvia Holdings Inc. | Uses vendor | 3 |
| Icon Plc | Uses vendor | 3 |
Showing 5 of 49 relationships.
Latest dated events (1,175)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-10-05 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-10-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-10-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-09-30 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-09-18 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 1,175 events.
Biomarker capability evidence (2,034)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ABCC6 | Trial sponsor | Named in trial inclusion criteria |
| ACE | Trial sponsor | Named in trial inclusion criteria |
| ACE | Trial sponsor | Named in trial inclusion criteria |
| ADPRS | Trial sponsor | Named in trial inclusion criteria |
| ADPRS | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 2,034 evidence rows.
On Scientist.com
Daiichi Sankyo (Germany) is listed as a research supplier in the Scientist.com network.
Service areas
Daiichi Sankyo focuses on pharmaceutical research and drug development.
- Website
- www.daiichisankyo.com
Not on this page
Checked, with nothing recorded for this organization: related companies not grouped here, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda recalls, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.
Work with Daiichi Sankyo on Scientist.com
For prices, more details, or to contact Daiichi Sankyo, visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.